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Abstract
The endogenous Staphylococcus aureus sortase A (SrtA) transpeptidase covalently
anchors cell wall-anchored (CWA) proteins equipped with a specific recognition motif
(LPXTG) into the peptidoglycan layer of the staphylococcal cell wall. Previous in situ experi-
ments have shown that SrtA is also able to incorporate exogenous, fluorescently labelled,
synthetic substrates equipped with the LPXTGmotif (K(FITC)LPETG-amide) into the bacte-
rial cell wall, albeit at high concentrations of 500 μM to 1 mM. In the present study, we have
evaluated the effect of substrate modification on the incorporation efficiency. This revealed
that (i) by elongation of LPETG-amide with a sequence of positively charged amino acids,
derived from the C-terminal domain of physiological SrtA substrates, the incorporation effi-
ciency was increased by 20-fold at 10 μM, 100 μM and 250 μM; (ii) Substituting aspartic
acid (E) for methionine increased the incorporation of the resulting K(FITC)LPMTG-amide
approximately three times at all concentrations tested; (iii) conjugation of the lipid II binding
antibiotic vancomycin to K(FITC)LPMTG-amide resulted in the same incorporation levels
as K(FITC)LPETG-amide, but much more efficient at an impressive 500-fold lower sub-
strate concentration. These newly developed synthetic substrates can potentially find broad
applications in for example the in situ imaging of bacteria; the incorporation of antibody
recruiting moieties; the targeted delivery and covalent incorporation of antimicrobial com-
pounds into the bacterial cell wall.
Introduction
Staphylococcus aureus infections are complex events that occur at the interface of the host and
the pathogen [1]. From a bacterial perspective, infections require expression of virulence fac-
tors including cell wall-anchored (CWA) proteins [2]. The C-terminal region of staphylococcal
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CWA proteins contains a cluster of positively charged amino acids, which positions the CWA
protein precursors to the cytoplasmic side of the bacterial cell membrane, and a hydrophobic
transmembrane domain that immobilizes CWA protein precursors within the cell membrane,
facilitating further processing by membrane-associated sortase A (SrtA) [3, 4]. The SrtA
enzyme recognizes the LPXTG motif of these proteins and catalyses their cleavage between
threonine and glycine residues [5]. Next, SrtA catalyses a transpeptidation reaction by which
the proteins are covalently linked to the peptidoglycan precursor lipid II [6–8]. Then, the pepti-
doglycan precursor moiety that is coupled to lipid II is incorporated following transglycosyla-
tion. SrtA is therefore closely involved in the control of S. aureus virulence [9–12].
In previous studies, it has been demonstrated that endogenous SrtA is also able to incorpo-
rate exogenously added K(FITC)LPETG-amide, a fluorescently labelled artificial SrtA sub-
strate, into the cell wall of S. aureus strains and of other Gram-positive bacteria. This required,
however, high substrate concentrations, in the mM range [13, 14]. The present study was
aimed at the development of novel SrtA substrates exhibiting improved incorporation effi-
ciency. In our view, such substrates might find applications in for example in situ imaging, the
incorporation of antibody recruiting moieties, and the targeted delivery and covalent incorpo-
ration of antimicrobial compounds into the bacterial cell wall.
In the present study a number of novel SrtA substrates were developed and their covalent
incorporation into the staphylococcal cell wall was characterised in situ. Three different types
of substrate modifications were explored: (i) variants of the K(FITC)LPETG-amide, which had
been elongated with sequences derived from physiological SrtA substrates—sequences contain-
ing a hydrophobic membrane spanning domain linked to a stretch of positively charged amino
acids; (ii) a substrate (K(FITC)LPMTG-amide) in which glutamate (E) was substituted for
methionine (M), which appeared to be better processed by SrtA in vitro [15] and (iii) K(FITC)
LPMTG-amide conjugated to vancomycin, designed to potentially improve the targeting to
lipid II, the primary acceptor for physiological SrtA substrates in S. aureus.
Materials and Methods
Solid-phase peptide synthesis
SrtA substrates were manufactured by solid-phase peptide synthesis using 9-fluorenyl-methox-
ycarbonyl (Fmoc)-chemistry with a Syro II synthesizer (Biotage EU Customer Service, Upp-
sala, Sweden) essentially as described previously [13, 14, 16]. Since the presence of a carboxylic
acid group at the C-terminus of the SrtA recognition motif (LPXTG) may inhibit SrtA activity,
an amide group was incorporated at this position [17]. Peptide synthesis grade solvents were
obtained from Actu-All Chemicals (Oss, The Netherlands), the preloaded NovaSyn TGA resins
from NovaBiochem (Merck Schuchardt, Hohenbrunn, Germany) and the N-α-Fmoc-amino
acids from Orpegen Pharma (Heidelberg, Germany) and Iris Biotech (Marktredwitz, Ger-
many). The composition of all synthetic substrates (substrates 1–13) is shown in Table 1.
FITC- labelling
Peptides were labelled with FITC (Fluorescein isothiocyanate) as the final step of the solid-
phase synthesis by coupling FITC to the ε-aminogroup of the N-terminal lysine residue which
was introduced using Boc-Lys(ε Fmoc)-OH [14].
‘Click’ addition of vancomycin
A previously-described alkyne-modified vancomycin building block was prepared by coupling
N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)pent-4-ynamide to the vancomycin
LPXTG Substrate Optimization
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C-terminus [18]. N-(3-(2-(2-(3-aminopropoxy) ethoxy)ethoxy)propyl)pent-4-ynamide was
prepared by first mono-Boc protecting one amino group of 4,7,10-Trioxa-1,13-tridecanedia-
mine with 1 equiv. Boc according to literature protocols [19] after which 4-pentynoic acid was
coupled [20]. Removal of the Boc group was accomplished using standard conditions (1:1 tri-
fluoroacetic acid/ dichloromethane (TFA/DCM), 1 hr) to provide the TFA salt of the desired
product as a light yellow oil that was used directly after evaporation of TFA and DCM. Vanco-
mycin (AppliChem, Darmstadt, Germany) was conjugated to the amino-alkyne spacer as fol-
lows: N-(3-(2-(2-(3-aminopropoxy) ethoxy)ethoxy)propyl)pent-4-ynamide (250 mg, 0.63
mmol, 3 equiv.) was dissolved in DMF (10 ml) followed by addition of triethylamine (351 μl,
2.52 mmol, 4 equiv.), vancomycin-HCl (936 mg, 0.63 mmol, 1.0 equiv.), EDAC (133 mg, 0.69
mmol, 1.1 equiv.) and HOBt (102 mg, 0.76 mmol, 1.2 equiv). The reaction mixture was stirred
at ambient temperature for 2 days after which the DMF was removed in a vacuum concentrator
(CHRIST, Osterode am Harz, Germany) and the residue was purified using preparative
RP-HPLC as described below for peptide purification. The vancomycin-alkyne conjugate was
next coupled to the azide-containing peptide by means of Cu(I) catalyzed ‘click’ chemistry fol-
lowing a procedure described previously [21]. The azido peptide was prepared by introducing
L-azidolysine (Fmoc-Lys(N3)-OH) (obtained from Chiralix, Nijmegen, The Netherlands). To
perform the ‘click’ reaction, the vancomycin alkyne was added in equimolar concentrations to
the resin-bound azido peptide in a 20 ml syringe, containing DMF (5 ml), 2 equiv. of 2,6-luti-
dine, 2 equiv. 2,2-bipyridine, 1 equiv. CuBr and 2 equiv. of sodium ascorbate (all peptide grade,
Actu-All Chemicals) and flushed for 1 min with N2. After incubation for 24 hrs at ambient
temperature the mixture was flushed sequentially with DMF, H2O, MeOH, EDTA (100 mM),
H2O, and DMF followed by washing and drying by flushing three times with isopropanol and
DCM each. Next the peptide was detached from the resin and purified as described below for
peptide purification.
Peptide purification
Peptides were purified by preparative RP-HPLC (Dionex Ultimate 3000, Thermo Scientific,
Breda, The Netherlands) on a Grace Spring column (250 mm x 25 mm, Grace, Deerfield, IL,
USA) containing Vydac C18 TP beads,10 μm (Vydac, Hesperia, CA, USA). Elution was per-
formed with a linear gradient from 15 to 45% AcN containing 0.1% TFA in 20 min at a flow
Table 1. Synthetic substrate amino acid sequences used in this study [13].
Substrate number N-term Substrate sequence C-term
1 K(FITC) LPETG amide
2 K(FITC) EGTLP amide
3 K(FITC) AKKSELPETGGEESTNKGMLFGGLFSILGLALLRRNKKNHK amide
4 K(FITC) AKKSELPETGGEESTNKRRNKKNHKAGMLFGGLFSILGLALL amide
5 K(FITC) AKKSELPETGGEESTNKRRNKLKNHK amide
6 K(FITC) LPETGGEESTNKRKKW amide
7 K(FITC) LPMTG amide
8 K(FITC) K(Vancomycin)LPMTG amide
9 K(FITC) K(Vancomycin)MGTLP amide
10 K(FITC) LPMTGG-K(vancomycin) amide
11 K(FITC) Vancomycin-K-AKKSELPETGGEESTNKRRNKLKNHK amide
12 K(Vancomycin)LPMTG amide
13 K(Vancomycin)MGTLP amide
doi:10.1371/journal.pone.0147401.t001
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rate of 20 ml/min. The absorbance of the column effluent was monitored at 214 nm, and peak
fractions were pooled and lyophilized. Re-analysis by RP-HPLC on an analytic Vydac C18-col-
umn (218MS54) developed with a similar gradient at a flow rate of 1 ml/min revealed a purity
of at least 95%. The authenticity was confirmed by mass spectrometry with a Microflex LRF
MALDI-TOF, equipped with a gridless reflectron (Bruker Daltonik GmbH, Bremen,
Germany).
Bacterial strains
The S. aureus 8325–4 wild type (WT) strain and its isogenic srtA deletion mutant (srtA KO)
were used in this study. The srtAmutant was generated by srtA:ermC allele transduction, as
previously described [9, 13]. The srtA KOmutant was selected and maintained on brain-heart
infusion agar (BHA, BD (Becton Dickinson and Company)-Difco, Etten-Leur, The Nether-
lands) plates supplemented with 3 μg/ml erythromycin (Abbott Laboratories, North Chicago,
Illinois, U.S.).
In situ incorporation of SrtA substrates
WT and srtA KO strains were grown overnight on respectively BHA and BHA supplemented
with 3 μg/ml erythromycin. Subsequently, bacteria were resuspended in Luria-Bertani medium
(LB, BD-Difco, Etten-Leur, The Netherlands), to an OD600nm of 0.1. Twenty-five microliters of
bacterial suspension was mixed with 25 μl LB containing up to 1 mM substrate (Table 1). Bac-
teria were then cultured in 96 wells-plates until the late stationary phase (approximately 24
hrs) in the dark at 37°C with continuous shaking at 230 rpm. As additional controls, we used
0.5 or 1 μM vancomycin and a combination of vancomycin with substrate 7 at 0.5 or 1 μM.
Flow cytometry
The bacteria were washed four times with PBS followed by centrifugation for 5 min at 3,700 x
g. To remove the non-covalently bound and intracellular substrate, bacteria were washed with
1% of sodium dodecyl sulphate (SDS, Merck-Schuchardt OHG, Hohenbrunn, Germany) at
60°C for 5 min. Subsequently, bacteria were washed four times with PBS followed by centrifu-
gation for 5 min at 3,700 x g. Labelled bacteria were resuspended in 100 μl of 4% formaldehyde
(Sigma-Aldrich, Zwijndrecht, The Netherlands) in PBS and incubated for 45 min at ambient
temperature with continuous agitation. After 3 washes with PBS, the bacteria were resuspended
in 0.5 ml PBS. The bacteria-associated fluorescence was measured on a FACS Canto II™ flow
cytometer and analysed using FacsDiva™ software (BD Biosciences, Breda, The Netherlands)
[13].
Effect of growth phase on substrate 5 incorporation
Substrate 5 (Table 1) incorporation was characterized in greater detail due to its enhanced
incorporation levels. Bacteria were cultured in LB medium in the continuous presence of either
(i) 1 mM substrate 1 or (ii) 250 μM substrate 5 until either a) exponential growth phase
(OD600nm 0.5), b) post-logarithmic growth phase (OD600nm 1), c) late exponential growth
phase (OD600nm 1.2) or d) late stationary growth phase (24 hrs incubation) in the dark at 37°C
with continuous shaking (230 rpm). After the various growth phases had been reached, bacte-
ria were harvested and the incorporation of substrates was established by determining the pres-
ence of FITC using FACS analysis.
In another experiment, bacteria were cultured (LB medium) in the absence of substrate to
the late stationary growth phase. Subsequently the bacteria were diluted to an OD600nm of 0.5,
LPXTG Substrate Optimization
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washed 3 times with PBS, and then incubated with either; i) SrtA buffer (50 mM Tris, 150 mM
NaCl, 10 mM CaCl2, pH 7.5), ii) substrate 1, or iii) substrate 5 (Table 1) in SrtA buffer. Bacteria
were incubated in the presence of 0 to 1 mM of these substrates using a final volume of 50 μl
and 96 wells-plates. Incubation was performed for 17 hrs in the dark at 37°C with continuous
shaking (230 rpm).
Determination of the minimal inhibitory concentration (MIC) of
vancomycin and vancomycin-conjugates
WT and srtA KO bacteria were cultured in LB medium in a 96-wells plate in the presence of
serial dilutions (0.1 to 100 μM) of either vancomycin (Sigma-Aldrich, Zwijndrecht, The Neth-
erlands) or substrate 8; 9; 12 or 13 at 37°C with continuous shaking (230 rpm). After 24 hrs,
the wells were visually inspected and the first clear well was designated as the MIC.
All experiments were repeated independently three times and the standard error of the
mean (SEM) was calculated.
Statistical analysis
Statistical analysis was performed using the Prism 5.0 package (GraphPad software, San Diego,
CA, USA). We used one-way ANOVA testing with Bonferroni correction, considering
P< 0.05 as being statistically significant.
Results
Optimization of synthetic SrtA substrates
In vivo the incorporation of physiological SrtA substrates is determined by a recognition signal
in their C-terminus. The C-terminus contains three motifs: (A) the LPXTG SrtA recognition sig-
nal, (B) a hydrophobic transmembrane domain and (C) a cluster of cationic amino acid residues
(See Fig 1, native substrate). The LPXTGmotif protrudes from the outside of the bacterium, and
is linked via a hydrophilic negatively charged spacer GEESTNK to the transmembrane domain,
which in turn is connected to the cationic cluster at the cytosolic side of the membrane [4, 22,
23]. In a previous study, we found that an artificial motif (K(FITC)LPETG) (substrate 1, Fig 1,
Table 1) is covalently incorporated in a SrtA-dependent manner into the cell wall of S. aureus
[13]. In the present study, we first tested a series of artificial SrtA substrates equipped with the
additional domains B and C, to examine the effect on incorporation. To monitor their incorpo-
ration in the cell wall by FACS, the substrates were linked via an additional lysine (K) residue to
FITC. S. aureusWT and its isogenic srtA KO (control) were cultured in the presence of sub-
strates for 24 hrs. After washing, to remove non-covalently bound substrates, the cell-associated
fluorescence was determined by FACS analysis. A scrambled version of substrate 1 (K(FITC)
EGTLP, substrate 2, Fig 1, Table 1) was used as a negative control. S. aureus (WT) cultured in
the presence of 1 mM substrate 1 showed a mean fluorescence level of 840 FU (Fluorescence
Units). In the srtA KO strain little if any incorporation of substrate 1 was observed (70 FU). Cul-
turing in the presence of the scrambled substrate 2 did not result in any substantial incorpo-
ration, neither in the WT nor in the srtA KO strain (75 FU and 50 FU forWT and srtA KO
strains, respectively) (Fig 2). This confirms previous studies [13, 14] that the incorporation of
substrate 1 was mediated for> 90% by SrtA. We next tested a set of substrates that included the
native sequence of the C-terminal region of the fibronectin-binding protein (FnBP) of S. aureus
(substrate 3, Fig 1, Table 1) [24]. In substrate 3 (AKKSELPETGGEESTNKGMLFGGLFSILGLA
LLRRNKKNHK), the LPETGmotif is separated from the hydrophobic (GMLFGGLFSILGLAL
L) and cationic (RRNKKNHK) domains by the negatively charged sequence GEESTNK, which
LPXTG Substrate Optimization
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functions as a hydrophilic spacer. Substrate 3 is flanked at the N-terminal part with a sequence
of non-repetitive region of cell wall-spanning domain AKKSE to increase the targeting towards
the cell-wall. Incorporation of substrate 3 in S. aureusWTwas comparable to that observed with
substrate 1, with a mean fluorescence intensity per cell of 800 FU at 1 mM. In contrast to sub-
strate 1, substrate 3 labelled also the srtA KO strain (400 FU at 1 mM) (Fig 2).
The position of the motifs A, B and C in substrate 3 is tailored for transferring physiological
SrtA substrates from the inside to the outside of the bacteria in situ. This configuration may
Fig 1. Schematic representation of the C-terminal region of FnBP precursor and synthetic substrates used in this study. 1: the minimal substrate
used, containing the SrtA recognition motif LPETG only (designated A). 2: the scrambled version of substrate 1, EGTLP. Native: the sorting motif of the FnBP
precursor of S. aureus, containing the SrtA recognition motif (A), a hydrophobic domain (B) and a positively charged region (C). The full sequences of the
separate regions are depicted under the blocks. Domain (A) and (B) are linked via a hydrophilic spacer GEESTNK [24]. The N-terminus and the C-terminus
are indicated with * and # respectively. 3: schematic representation of substrate 3, based on the complete sorting signal of the FnBP precursor. 4: schematic
representation of substrate 4, in which domain (B) and (C) are interchanged. 5: schematic representation of substrate 5, in which domain B is removed. 6:
schematic representation of substrate 6 containing domain (A), truncated domain (C) and a C-terminal tryptophan. 7: schematic representation of substrate 7
containing domain (A), with glutamate (E) substituted for methionine (M). 8: schematic representation of substrate 8, composed of substrate 7with its N-
terminus linked to vancomycin. 9: schematic representation of substrate 9, the scrambled version of substrate 8, with an MGTLPmotif instead of an LPMTG
motif. 10: schematic representation of substrate 10, composed of substrate 7 with its C-terminus linked to vancomycin. 11: schematic representation of
substrate 11, composed of substrate 5 with its N-terminus linked to vancomycin. All substrates were at the N-terminus labelled with a FITC group.
doi:10.1371/journal.pone.0147401.g001
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therefore be sub-optimal for the incorporation of exogenous substrates, which target the
endogenous SrtA from the outside. We therefore examined whether interchanging the posi-
tions of the membrane-spanning domain (B) and the cationic cluster (C) (substrate 4, Fig 1,
Table 1) would result in a higher incorporation. This peptide, however, labelled S. aureusWT
and S. aureus srtA KO to the same extent (1600 versus 1400 FU) (Fig 2). Substrates 3 and 4
formed precipitates during incubation, due to their hydrophobic character, which could not be
completely removed in the washing steps and stayed attached to the bacteria. We envisage that
this has caused the SrtA-independent background labelling of the S. aureus srtA KO strain.
Because of the poor solubility, substrates 3 and 4 were not further examined. We next tested
substrate 5 (Fig 1, Table 1), which lacks the hydrophobic membrane-spanning domain (B).
This substrate was incorporated at a higher efficiency compared to substrate 1 (Fig 2). Between
10 and 250 μM the incorporation of substrate 5 increased almost linearly with the concentra-
tion. In this concentration range, substrate 5 showed an approximately 20-fold higher incorpo-
ration than substrate 1. At concentrations> 250 μM, the incorporation of substrate 5 levelled
off, suggesting that the process became saturated. Substrate 5 revealed a higher background in
srtA KO strain than substrate 1 (860 vs 70 fluorescence units at 1 mM, Fig 2). This is probably
caused by SrtA independent electrostatic interactions between the cationic cluster and the bac-
terial cell surface. Still, the incorporation of substrate 5 in the S. aureusWT strain was 10 to
20-fold higher than in the S. aureus srtA KO strain, indicating that> 90% of the incorporation
of substrate 5 was mediated by SrtA, similar to that of substrate 1. In an attempt to further min-
imize the substrate, a variant (LPETGGEESTNKRKKW (substrate 6, Fig 1, Table 1)) was
developed composed of the SrtA recognition motif LPETG, linked via the GEESTNK linker to
Fig 2. Titrations of the SrtA synthetic substrates. Cultures of 8325–4WT and srtA KO strains were incubated in LB medium during 24 hrs in the presence
of either substrate 1; 2; 3; 4; 5 or 6 [13] at 10 μM, 100 μM, 250 μM, 500 μM or 1 mM and analysed by FACS. The synthetic substrate concentrations used are
depicted on the X-axis and the mean fluorescence, as a measure for the level of substrate incorporation into the bacterial cell wall, was plotted on the Y-axis.
Substrate 1 signal at 100 μM and 250 μMwas significantly lower than the signals obtained with substrate 5 at the same concentration (P < 0.0001). Substrate
1 signal obtained at 1 mM was significantly lower than the signal obtained with substrate 5 at 100 μM (P < 0.0001). Only the most relevant significant
differences are presented.
doi:10.1371/journal.pone.0147401.g002
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a minimal cationic domain C (RKK) and terminated at the C-terminus by a tryptophan (W)
residue. As this residue has a preference for the membrane-water interface [25, 26], we rea-
soned that it might target the substrate to the bacterial membrane. The efficiency of this pep-
tide, however, did not differ from that of substrate 1 (700 FU; 1 mM), with the background
labelling of 160 FU at 1 mM (Fig 2).
Effect of growth phase on substrate incorporation
To analyse the effect of growth phase on the cumulative incorporation of the SrtA substrates, S.
aureus (WT and srtA KO strains) were cultured in the presence of substrate 1 and 5, at a con-
centration that yielded the maximal incorporation level (1 mM and 250 μM, respectively). Bac-
teria were harvested after 4 hr (exponential phase), 7 hr (post-logarithmic phase), 8.5 hr (late
exponential phase) and 24 hr (late stationary phase) and analysed by FACS (Fig 3A). After 8.5
hrs both substrates showed comparable incorporation (approximately 500 and 300 FU, respec-
tively). Between 8.5 and 24 hrs the incorporation of substrate 1 increased approximately three-
fold, whereas that of substrate 5 increased more than 60-fold (from 300 to 19,000 FU; Fig 3A).
We then explored the incorporation of substrate 5 in late stationary S. aureus. To do so, S.
aureus was cultured until late stationary phase in the absence of substrates. After washing, bac-
teria were transferred into SrtA reaction buffer (conditions where the bacterial metabolism is
suppressed) supplemented with either substrates 1 or 5 at concentrations varying between
10 μM to 1 mM. After 17 hrs, the reaction was stopped and incorporation was determined by
FACS; bacteria treated with substrate 5 displayed a 4 to 10 times higher fluorescence than
those incubated with substrate 1 (Fig 3B). This supported that substrate 5 was incorporated
with a higher efficiency than substrate 1.
Fig 3. Kinetics determination of substrate 5. 8325–4WT and srtA KO strains were incubated in the presence of (A) either 1 mM of substrate 1 or 250 μM of
substrate 5 until either exponential (4 hrs), post-logarithmic (7 hrs), late exponential (8.5 hrs) or late stationary phase (24 hrs) in LB medium. The mean
fluorescence of substrate 1 and substrate 5 is depicted on y-axis. (B) Washed and diluted (OD600nm 0.5) late stationary grownWT and srtA KO bacteria were
incubated with either 10 μM, 100 μM, 250 μM, 500 μM or 1 mM substrate 1 or substrate 5 in SrtA buffer during 17 hrs. The mean fluorescence was
determined by FACS. The signal obtained with substrate 1 at 1 mM after 24 hrs of incubation was significantly lower than the signal obtained with substrate 5
at 250 μM after 24 hrs (P < 0.001). Substrate 5 signals at time points 4 hrs, 7 hrs and 8 hrs were all significantly lower in comparison to the signal obtained
with the same substrate at 24 hrs time point at 250 μM (P < 0.001).
doi:10.1371/journal.pone.0147401.g003
LPXTG Substrate Optimization
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Effect of glutamate to methionine substitution
The third position in the SrtA recognition motif (LPXTG) is tolerant to various amino acids
substitutions. Still, some residues are preferred over others, e.g. LPMTG is more rapidly pro-
cessed than LPETG by isolated recombinant SrtA in vitro [15]. Therefore, we examined if
substituting E for M (substrate 7, Fig 1, Table 1) would also enhance the in situ processing of
exogenous SrtA substrates. Substrate 7 was incorporated significantly better than substrate 1
into the WT bacterial surface at 500 μM and 1 mM (Fig 4). Substrate 7 showed little if any
incorporation in srtA KO strain (150 FU), indicating that its incorporation in S. aureusWT
required a functional SrtA.
Effect of vancomycin conjugation on incorporation
The glycopeptide antibiotic vancomycin targets the D-ala-D-ala motif of lipid II, which in vivo
functions as an acceptor for SrtA-processed CWA proteins. Vancomycin binds specifically to
lipid II and decreases its accessibility, thereby interfering with SrtA-dependent anchoring of
CWA proteins [7, 27, 28]. Conjugation of vancomycin to substrate 7 was therefore considered
as an attractive strategy to enhance the targeting of these substrates to the vicinity of SrtA. To
do so, vancomycin was coupled to substrate 7 at either the penultimate N-terminal position to
yield K(FITC)K(vancomycin)LPMTG (substrate 8, Fig 1, Table 1) or the C-terminal site of the
peptide, to yield K(FITC)LPMTGGK(vancomycin) (substrate 10, Fig 1, Table 1). As a control
served substrate 9 (K(FITC)K(vancomycin)MGTLP), a scrambled variant of substrate 8 (Fig 1,
Table 1). The in situ incorporation of the vancomycin-LPMTG conjugates was assessed by cul-
turing S. aureus in LB medium supplemented with the substrates at concentrations varying
from 0.5 μM—5 μM (Fig 5). This revealed that the vancomycin-modified substrates 8 and 10
(the latter not shown) were incorporated to the same extent as the parent peptide 7, but at a
200-fold lower concentration (Fig 5). Culturing in the presence of equimolar concentrations of
vancomycin and substrate 7 did not result in labelling of S. aureus, ruling out that vancomycin
by itself stimulated the incorporation of substrate 8 and 10 (Fig 5). At the highest
Fig 4. Incorporation of substrate 7.WT and srtA KO S. aureus bacteria were incubated in the presence of
either substrate 1 or substrate 7 at 10 μM, 100 μM, 250 μM, 500 μM or 1 mM concentrations in LB medium
during 24 hrs and analysed by FACS. The incorporation of substrate 7was significantly higher at 500 μM and
at 1 mM compared to substrate 1 at the same concentrations after 24 hrs in WT bacteria (P < 0.001).
doi:10.1371/journal.pone.0147401.g004
LPXTG Substrate Optimization
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concentration tested (5 μM), background labelling of substrate 8 with the srtA KO strain was
observed, possibly due to formation of non-covalent complexes of vancomycin with its D-ala-
D-ala ligand. Similarly, the control substrate 9 also showed background staining with both the
WT and the srtA KO strain at higher substrate concentration. The specific substrate incorpo-
ration of substrate 8 in WT bacteria was 10- fold higher than in the S. aureus srtA KO strain
incubated with substrate 8 and srtA KO andWT strains incubated with control substrate 9.
These data indicate that> 90% of the incorporation of substrate 8 was mediated by SrtA. Con-
jugation of vancomycin to substrate 5 (substrate 11, Fig 1, Table 1) did not result in the same
increased incorporation observed for conjugates 8 and 10 (data not shown).
Apparently, coupling of LPMTG to vancomycin enhanced the processing by SrtA. We won-
dered if, reciprocally, LPMTG would enhance the targeting of vancomycin to lipid II, and
henceforth its antibacterial activity. Determination of the MIC-values of substrate 8 and 9,
however, showed that conjugation of vancomycin with LPMTG negatively affects its antimi-
crobial activity, causing an increase in the MIC of vancomycin from 1 μM to either 50 or
100 μM for substrate 8 and 9, respectively, in both the WT and the srtA KO strain (Fig 6). To
test the effect of vancomycin modification on MIC increase within the substrate 8 and 9, we
generated substrate 12 and 13 lacking the FITC molecule. The MIC of these non-FITCylated
variants were 2 μM (substrate 12) and 50 μM (substrate 13) (Fig 6). These data suggest, that
the addition of FITC molecule decreases the antimicrobial activity of the vancomycin unit
within the synthetic substrate.
Discussion
In the present study, we have examined the effect of various modifications on the incorporation
efficiency of artificial SrtA substrates. Physiological SrtA substrates contain, besides the
Fig 5. Incorporation of vancomycin—conjugated substrate. 8325–4WT and srtA KO bacteria were incubated in the presence of either 0.5 μM or 1 μM of
1) vancomycin; 2) substrate 7 + vancomycin; or 0.5 μM; 1 μM; 2 μM or 5 μM of 3) substrate 7; 4) substrate 8 or 3) substrate 9 in LB medium during 24 hrs and
analysed by FACS (mean fluorescence). (***: P < 0.0001).
doi:10.1371/journal.pone.0147401.g005
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LPXTG motif, a hydrophobic transmembrane domain and a cluster of positively charged
amino acids, which together retain the protein in the vicinity of the bacterial membrane [4]. In
vivo, this prevents leakage of key CWA surface proteins into the bacterial surroundings, and
facilitates efficient processing by SrtA. By elongating the LPXTG motif with these domains, we
aimed to improve the in situ processing of synthetic SrtA substrates. However, substrates 3 and
4 equipped with both the hydrophobic membrane-spanning and the cationic domain, were
poorly soluble and formed visible aggregates. This probably caused high non-specific adsorp-
tion to bacterial surfaces (see Fig 2). Omitting the hydrophobic domain (substrate 5), however,
resulted in 5-fold better incorporation than the parent substrate. Also substrate 5 exhibited
more a-specific binding to the srtA KO strain than the parent peptide 1, probably due to a
strong electrostatic binding with the bacterial surface. The incorporation of substrate 5 reached
saturation at concentrations 250 μM. This suggests that under these conditions another fac-
tor, likely the number of accessible pentaglycine acceptors, had become limiting [29, 30]. Strik-
ingly, even in the presence of these saturating concentrations of exogenous substrate, the cell-
wall expression of the endogenous substrate SpA was not decreased (Hansenova Manaskova
et al, unpublished observations), indicating that this physiological substrate is preferentially
processed by SrtA. In line, incorporation of SpA predominantly occurs in the exponential
growth phase [31], whereas incorporation of substrates 5 (Fig 3) and substrate 1 [13] mainly
takes place in the stationary phase, when the synthesis of CWAs is subdued [31].
Substitution of E by M within the LPXTG motif (substrate 7) resulted in a 3-fold higher
incorporation. This is in a close agreement with the results of a previous study, which found
that LPMTG in vitro is cleaved by recombinant SrtA approximately 2.5 times faster than
Fig 6. MIC determination of vancomycin-conjugated substrates.WT and srtA KO bacteria were cultured in LB medium in the presence of serial dilutions
(0.1 to 100 μM) of either vancomycin or substrate 8; 9; 12 or 13 at 37°C with continuous shaking (230 rpm) during 24 hrs. The MIC-value (first clear well) was
visually determined after 24 hrs and is indicated with an arrow.
doi:10.1371/journal.pone.0147401.g006
LPXTG Substrate Optimization
PLOS ONE | DOI:10.1371/journal.pone.0147401 January 22, 2016 11 / 14
LPETG [15]. Interestingly, the SrtA recognition motifs of different native CWA proteins con-
tain various different amino acids at the ambiguous third position: lysine, glutamic acid, aspar-
tic acid, alanine or glutamine, but none of them contains methionine [32].
Conjugation of LPMTG to vancomycin enhanced the incorporation efficiency drastically:
the same level of incorporation was obtained at 200- to 500-fold lower concentrations than
with the unconjugated substrate (Fig 5). SrtA-independent labelling of the S. aureusWT and
the S. aureus srtA KO strain was observed with substrate 8 and the scrambled substrate 9, pos-
sibly caused by vancomycin direct binding to D-ala-D-ala. Interestingly, conjugation of the
peptide moiety to vancomycin increased the MIC value 50- to 100-fold, in line with similar
decreases in antibiotic activity observed for other fluorescently-labelled vancomycin probes,
which despite a>100-fold increase in MIC value, labelled the bacterial cell wall at sub-MIC
concentrations [33]. The fluorescent label in vancomycin substrates seems to be responsible for
the MIC increase, as substrate 12 (substrate 8 variant without FITC) had comparable MIC
value to vancomycin molecule only (2 μM and 1 μM, respectively).
In summary, we have demonstrated that modification of SrtA synthetic substrates is a feasi-
ble approach to enhance their in situ incorporation by endogenous S. aureus SrtA. Interest-
ingly, we found that vancomycin-LPMTG conjugates are incorporated in the cell wall of S.
aureus with high efficiency. Such molecules may form a platform for targeted modification of
the bacterial surface for e.g. antimicrobial or imaging purposes.
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